Health authorities in the US have recommended a pause in the use of the Johnson and Johnson Covid vaccine over blood clot concerns
In a joint statement, the Federal Drug Administration and the Centers for Disease Control say the move is out of an abundance of caution.
It's after 6 reported US cases of a rare and severe type of blood clot in individuals after receiving the vaccine, out of almost 7 million doses administered.
The FDA says the adverse events appear to be extremely rare.
Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution.
— U.S. FDA (@US_FDA) April 13, 2021
On April 1st, Minister for Health Stephen Donnelly signed the approval for the J&J vaccine to be rolled out in Ireland following the EMA's decision, the first deliveries of which were expected this month.
According to figures published by the Department of Health last week, 40,800 doses of the J&J vaccine were due to be delivered to Ireland in April, followed by 132,000 in May and 432,000 in June.
